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Decreased long noncoding RNA 
SPRY4-IT1 contributing to gastric cancer cell 
metastasis partly via affecting epithelial–
mesenchymal transition
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Abstract 
Background: Long noncoding RNAs (lncRNAs) are emerging as key regulators governing fundamental biological 
processes, and their disorder expression involves in tumorigenesis. SPRY4‑IT1 (SPRY4 intronic transcript 1), a lncRNA 
derived from an intron within SPRY4 gene, involves in multiple cancers development. However, the expression pattern 
and biological function of SPRY4‑IT1 in gastric cancer is still not well documented. Hence, we carried out the present 
study to investigate the potential role of SPRY4‑IT1 in gastric carcinogenesis.
Methods: QRT‑PCR was performed to detect the expression of SPRY4‑IT1 in 61 pairs of gastric cancer samples. 
Over‑expression and RNA interference (RNAi) approaches were used to investigate the biological functions of SPRY4‑
IT1. The effect of SPRY4‑IT1 on proliferation was evaluated by MTT and colony formation assays. Gastric cancer cells 
transfected with pCDNA‑SPRY4‑IT1 were injected into nude mice to study the effect of SPRY4‑IT1 on tumorigenesis 
and metastasis in vivo. Protein levels of SPRY4‑IT1 targets were determined by western blot or fluorescence immuno‑
histochemistry. ChIP assays were performed to investigate the effect of DNMT1 on SPRY4‑IT1 expression. Differences 
between groups were tested for significance using Student’s t test (two‑tailed).
Results: SPRY4‑IT1 expression is decreased in gastric cancer tissues and associated with larger tumor size, advanced 
pathological stage, deeper depth of invasion and lymphatic metastasis. Patients with lower SPRY4‑IT1 expression had 
a relatively poor prognosis. DNA methylation may be a key factor in controlling the SPRY4‑IT1 expression. Further‑
more, SPRY4‑IT1 contributed to gastric cancer cells metastasis might partly via regulating epithelial–mesenchymal 
transition (EMT) process.
Conclusion: Low expression of SPRY4‑IT1 is involved in progression and metastasis of gastric cancer and may repre‑
sent a novel biomarker of poor prognosis in patients with gastric cancer.
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Background
Gastric cancer is the second leading cause of cancer 
related death worldwide, and gastric cancer remains one 
of the most common malignancies, especially in East 
Asia [1]. In most patients, gastric cancer is diagnosed at 
an advanced stage and is accompanied by malignant pro-
liferation, extensive invasion and lymphatic metastasis. 
Although the clinical outcome of gastric cancer has grad-
ually improved, the prognosis of patients with advanced 
disease is still disappointing and the 5-year survival rate 
of patients with gastric cancer still remains relatively low 
[2]. Recently, multiple lines of evidence have revealed 
the contribution of long non-coding RNAs (lncRNAs) in 
tumorigenesis [3]. Therefore, it is important to identify 
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gastric cancer related lncRNAs and investigate their roles 
in gastric carcinogenesis.
In the past decade, fast development of sequencing 
technique and completion of ENCODE (encyclopedia of 
DNA elements) project have led to the discovery of a new 
group of RNAs, known as lncRNAs. lncRNAs are more 
than 200 nt in length with limited or no protein-coding 
capacity, which is often expressed in a disease-, tissue- or 
developmental stage-specific manner [4–6]. Although 
lncRNAs are less well characterized compared with 
microRNAs, increasing evidence suggest that lncRNAs 
could play critical roles in regulation of diverse cellular 
processes such as stem cell pluripotency, cell differen-
tiation, cell growth, cell apoptosis and cancer metastasis 
[7–13]. Additionally, lncRNAs may function as cis- or 
trans-regulators of gene expression via playing as scaf-
folds for chromatin modifying complexes, decoys to tran-
scription factors or serving as ‘sponge’ to microRNAs 
[14–17].
SPRY4-IT1 (SPRY4 intronic transcript 1), a lncRNA 
derived from an intron within SPRY4 gene, has been 
recently revealed as oncogenic regulatory hubs or tumor 
suppressors in different cancers. SPRY4-IT1 was firstly 
reported to be over-expressed in melanoma cells, and 
knockdown of its expression inhibited cell growth, inva-
sion and induced cell apoptosis [11, 18]. Moreover, ele-
vated expression of SPRY4-IT1 was associated with poor 
prognosis of clear cell renal cell carcinoma and esopha-
geal squamous cell carcinoma [19, 20]. SPRY4-IT1 also 
involved in trophoblast cells proliferation, migration and 
apoptosis [21]. In previous study, we found that SPRY4-
IT1 is down-regulated in non small cell lung cancer, and 
SPRY4-IT1 could function as a tumor suppressor via 
regulating cell growth and invasion [22]. However, the 
expression pattern and biological roles of SPRY4-IT1 
in gastric cancer is not well documented. The purpose 
of this study is to investigate the expression pattern and 
clinical significance of SPRY4-IT1 in gastric cancer, and 
identify its key role in gastric cancer cell proliferation and 
metastasis. This study may advance our understanding of 
the role of SPRY4-IT1 as a regulator of pathogenesis of 
gastric cancer and facilitate the development of lncRNA-
directed diagnostics and therapeutics.
Methods
Tissue collection
61 Paired gastric cancer tissues and normal tissues were 
obtained from patients who had underwent surgery at 
Jiangsu province hospital between 2009 and 2011, and 
were diagnosed with gastric cancer (stages I, II, III, and 
IV; seventh edition of the AJCC Cancer Staging Man-
ual) based on histopathological evaluation. No local 
or systemic treatment was conducted in these patients 
before the operation. All specimens were immediately 
frozen in liquid nitrogen, and stored at −80 °C until RNA 
extraction. This study was approved by the Research Eth-
ics Committee of Nanjing Medical University, China. 
Informed consents were obtained from all patients.
Cell lines and culture conditions
Six gastric cancer cell lines (SGC7901, BGC823, 
MGC803, AGS, MKN45, MKN28, HCG-27), and a nor-
mal gastric epithelium cell line (GES-1) were purchased 
from the Institute of Biochemistry and Cell Biology of the 
Chinese Academy of Sciences (Shanghai, China). Cells 
were cultured in RPMI 1640 or DMEM (GIBCO-BRL) 
medium supplemented with 10% fetal bovine serum (10% 
FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin 
in humidified air at 37°C with 5% CO2.
RNA extraction and qRT‑PCR analysis
Total RNA was extracted from tissues or cultured cells 
using TRIZOL reagent (Invitrogen, Carlsbad, CA). For 
qRT-PCR, 1  µg RNA was reverse transcribed to cDNA 
by using a Reverse Transcription Kit (Takara, Dalian, 
China). Real-time PCR analyses were performed with 
SYBR Premix ExTaq II kit (Takara, Dalian China). Results 
were normalized to the expression of GAPDH. The PCR 
primers were shown in Additional file  1: Table  S1. The 
qRT-PCR assays and data collection were performed on 
ABI 7500, and results were analyzed and expressed rela-
tive to threshold cycle values (ΔCt), then converted to 
fold changes using the 2−ΔΔCt method. GAPDH was used 
as an internal control.
Treatment cells with 5‑aza‑CdR
BGC823 and SGC7901 cells (2.5 × 105) were seeded into 
six-well culture plate on day 0 and exposed to 0, 5  µM 
5-aza-CdR(Sigma-Aldrich, USA)for 3  days. The cells 
treated with 5-aza-CdR were harvested and used for 
detection of SPRY4-IT1 expression.
Chromatin immunoprecipitation assays
The ChIP assays were performed using EZ-Magna CHIP 
KIT according to the manufacturer’s instruction (Mil-
lipore, Billerica, MA, USA). SGC7901 and BGC823 cells 
were treated with formaldehyde and incubated for 10 min 
to generate DNA–protein cross-links. Cell lysates were 
then sonicated to generate chromatin fragments of 200–
300 bp and immunoprecipitated with DNMT1 (Millipore) 
or the negative control IgG (Millipore). Anti-AcH3 (Mil-
lipore) was used as the positive control for the CHIP pro-
cedure. Precipitated chromatin DNA was recovered and 
analyzed by qRT-PCR (Additional file 1: Table S1).
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Transfection of gastric cancer cells
SPRY4-IT1 over-expression plasmid and siRNA has been 
described in previous study [22]. siRNAs for the human 
DNMT1 and the negative control olignucleotides were 
purchased from Invitrogen (Invitrogen, Carlsbad, CA, 
USA) (Additional file  1: Table  S1). All plasmid vectors 
for transfection (pCDNA-SPRY4-IT1 and empty vector) 
were extracted by DNA Midiprep or Midiprep kit (Qia-
gen, Hilden, Germany). Gastric cells cultured on six-well 
plate were transfected with the pCDNA-SPRY4-IT1, 
si-SPRY4-IT1 or si-DNMT1 using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Cells were harvested after 48 h for 
qRT-PCR and western blot analyses.
Cell proliferation assays
Cell proliferation was monitored using Cell Prolifera-
tion Reagent Kit I (MTT) (Roche Applied Science). Si-
SPRY4-IT1-transfected BGC823 cells (3,000/well), and 
pCDNA-SPRY4-IT1-transfected BGC823 or SGC7901 
cells (3,000/well) were allowed to grow in 96-well plates. 
Cell proliferation was documented every 24  h follow-
ing the manufacturer’s protocol. All experiments were 
performed in quadruplicate. For the colony formation 
assay, a total of 500 cells were placed in a fresh six-well 
plate and maintained in media containing 10% FBS, 
replacing the medium every 4  days. After 14  days, cells 
were fixed with methanol and stained with 0.1% crystal 
violet (Sigma-Aldrich). Visible colonies were manually 
counted. For each treatment group wells were assessed in 
triplicate.
Cell migration and invasion assays
For the transwell assays, at 48  h post-transfection, 
5 × 104 (migration) or 1 × 105 (invasion) cells in serum-
free media were placed into the upper chamber of an 
insert (8-μm pore size; Millipore, Billerica, MA, USA). 
Medium containing 10% FBS was added to the lower 
chamber. After incubation for 24  h, the cells remain-
ing on the upper membrane were removed with cotton 
wool, whereas the cells that had migrated or invaded 
through the membrane were stained with methanol and 
0.1% crystal violet, imaged, and counted using an IX71 
inverted microscope (Olympus, Tokyo, Japan). Experi-
ments were independently repeated three times.
Tumor formation assay in a nude mouse model
5  weeks female athymic BALB/c nude mice were 
maintained under pathogen-free conditions and 
manipulated according to protocols approved by the 
Committee on the Ethics of Animal Experiments of Nan-
jing medical University. BGC823 cells transfected with 
pCDNA-SPRY4-IT1 or empty vector were harvested 
from six-well cell culture plates and resuspended at a 
concentration of 1 × 108 cells/mL. A volume of 100 µL of 
suspended cells was subcutaneously injected into a single 
side of the posterior flank of each mouse. Tumor growth 
was examined every 3  days, and tumor volumes were 
calculated using the equation V = 0.5 × D × d2 (V, vol-
ume; D, longitudinal diameter; d, latitudinal diameter). 
At 15 days post injection, the mice were euthanized and 
tumor weights were measured and also used for further 
analysis.
Tail vein injection of cells for metastasis in athymic mice
5-weeks-old male athymic mice were purchased from 
the Animal Center of the Nanjing University (Nanjing, 
China) and maintained in laminar flow cabinets under 
specific pathogen-free conditions. BGC823 cells trans-
fected with pCDNA-SPRY4-IT1 or the empty vector 
were harvested from 6-well plates and resuspended at 
2 × 107 cells/mL. A volume of 0.1 mL of suspended cells 
was injected into the tail veins of mice, which were sac-
rificed 7  weeks after injection. The lungs were removed 
and photographed, and visible tumors on the lung sur-
face were counted. This study was carried out in strict 
accordance with the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. Our 
protocol was approved by the Committee on the Ethics 
of Animal Experiments of Nanjing Medical University. 
All surgery was performed under sodium pentobarbi-
tal anesthesia, and all efforts were made to minimize 
suffering.
Western blotting analysis
Cells were lysed with RIPA protein extraction reagent 
(Beyotime, Beijing, China) supplemented with a protease 
inhibitor cocktail (Roche, CA, USA). The concentration 
of protein was determined using the Bio-Rad protein 
assay kit. Protein extracts (40 µg) were separated by 10% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
then transferred to nitrocellulose membranes (Sigma) 
and incubated with antibodies. ECL chromogenic sub-
strate was used to visualize the bands and the intensity 
of the bands was quantified by densitometry (Quantity 
One software; Bio-Rad, CA, USA). GAPDH was used 
as a control. Antibodies against E-cadherin and Vimen-
tin (1:1,000 dilution) was purchased from Cell Signaling 
Technology (CST, MA, USA).
Fluorescence immunohistochemistry
BGC823 cells were fixed in 4% paraformaldehyde fol-
lowing a standard protocol. Rabbit anti-E-cadherin and 
Vimentin polyclonal antibodies (1:50; CST) were used 
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as primary antibodies, with TRITC-labeled anti-Rabbit 
IgG (1:200; Sigma-Aldrich, St. Louis, MO, USA) used 
as a secondary antibody. Sections were mounted onto 
slides using Gel Mount Aqueous Mounting Medium 
(G0918, Sigma-Aldrich, St. Louis, MO, USA) and exam-
ined with an Olympus BX51 microscope (Olympus, 
Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using the SPASS17.0 
statistical software package. The expression levels of 
SPRY4-IT1 in tumor tissues were compared with normal 
adjacent mucosa by Wilcoxon test, while the associations 
between SPRY4-IT1 expression and clinical character-
istics were evaluated by Chi square test. Survival curves 
were estimated by the Kaplan–Meier method. The log-
rank test was used to estimate the statistical differences 
between survival curves. A two-tailed P < 0.05 was con-
sidered significantly.
Results
Decreased expression of SPRY4‑IT1 in human gastric 
cancer
We firstly examined SPRY4-IT1 expression level in 61 
paired gastric cancer samples and adjacent normal tis-
sues using qRT-PCR approach, and gene expression was 
calculated relative to that of an internal control (ΔCt). As 
shown in Fig.  1a, the SPRY4-IT1 level was significantly 
down-regulated in gastric cancer tissue compared with 
corresponding adjacent non-tumor tissues. (P  =  0.001, 
Wilcoxon test). These data indicate that SPRY4-IT1 
expression may be related to gastric cancer pathogenesis.
Correlation between SPRY4‑IT1 expression 
and clinicopathological factors in gastric cancer
Moreover, the correlation between SPRY4-IT1 expres-
sion and clinicopathological parameters were examined. 
According to the median ratio of relative SPRY4-IT1 
expression (0.535), the 61 gastric cancer patients were 
classified into two groups: relative high-SPRY4-IT1 
group (n  =  30, SPRY4-IT1 expression ratio  ≥  median 
ratio) and relative low-SPRY4-IT1 group (n = 31, SPRY4-
IT1 expression ratio ≤ median ratio) (Fig. 1b). Decreased 
SPRY4-IT1 expression was significantly associated with 
larger tumor size (P  =  0.041), advanced pathological 
stage (P =  0.028), deeper depth of invasion (P  <  0.001) 
and lymphatic metastasis (P = 0.021). However, SPRY4-
IT1 expression was not associated with other parameters 
such as age (P = 0.446), gender (P = 0.300) tumor loca-
tion (P = 0.931) and histologic differentiation (P = 0.155) 
in gastric cancer (Table  1). Thus, down-regulation of 
SPRY4-IT1 might have important roles in gastric cancer 
development and progression.
Association between SPRY4‑IT1 expression and patients’ 
survival
We further examined whether SPRY4-IT1 expression 
level correlated with outcome of gastric cancer patients. 
Overall survival (OS) and disease-free survival (DFS) 
curves were plotted according to SPRY4-IT1 expression 
level by the Kaplan–Meier analysis and log-rank test. 
Remarkably, patients with low SPRY4-IT1 expression 
level had poorer disease-free survival (P  =  0.002) and 
overall survival (P = 0.001) (Fig. 1c, d). The overall 3-year 
survival rates of patients with high SPRY4-IT1 expres-
sion were 40%, while 25.8% for patients with low SPRY4-
IT1 expression indicated a shorter overall survival time 
Table 1 Correlation between  SPRY4-IT1 expression 
and clinicopathological characteristics in gastric cancer
Clinical  
parameter
SPRY4‑IT1 SPRY4‑IT1 Chi‑squared test 
P valueHigh no. cases Low no. cases
Age (years) 0.446
 <50 13 17
 >50 17 14
Gender 0.300
 Male 16 21
 Female 14 10
Location 0.931
 Distal 11 12
 Middle 12 13
 Proximal 7 6
Size 0.041*
 >5 cm 11 20




 Well 2 2
 Moderately 12 7
 Poorly 14 17
 Undifferentiated 2 5
Invasion depth <0.001*
 T1 11 3
 T2 12 5
 T3 4 12
 T4 3 11
TNM stages 0.028*
 I 8 1
 II 12 10
 III 9 17




 Yes 11 21
 No 19 10
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of patients (median OS: 14 months) compared with high 
SPRY4-IT1 expression (median OS: 22 months). Moreo-
ver, 3  years of disease-free survival for high SPRY4-IT1 
expression was 30%, while was 9.7% for low SPRY4-IT1 
expression. The median survival time for high SPRY4-
IT1 expression is 18  months, while is 9  months for low 
SPRY4-IT1 expression. These results suggested reduced 
SPRY4-IT1 expression in gastric cancer may represent a 
novel indicator of poor prognosis in gastric cancer.
DNMT1 suppresses SPRY4‑IT1 expression in gastric cancer 
cells
To explore the mechanism of decreased expression 
of SPRY4-IT1, qRT-PCR was performed to detect the 
expression of SPRY4-IT1 in a variety of cell lines. The 
results showed that SPRY4-IT1 expression was sig-
nificantly down-regulated in gastric cancer cells when 
compared with GES-1 (Fig.  2a). We hypothesized that 
epigenetic modification may be involved in aberrant 
SPRY4-IT1 transcriptional inactivation. Bioinformatic 
analysis identified a canonical CpG island in the promoter 
region of the SPRY4-IT1 loci, as described in our pre-
vious study [22]. In addition, we found that SPRY4-IT1 
expression was significantly increased by 3.7- and 2.8-
fold in 5-aza-CdR treated cells (BGC823 and SGC7901) 
compared with respective controls (Fig.  2b). Moreover, 
knockdown of DNMT1 expression could also up-regulate 
SPRY4-IT1 expression in BGC823 and SGC7901 cells 
(Fig.  2c). To further investigate whether DNMT1 could 
directly bind to SPRY4-IT1 promoter region, chromatin 
Fig. 1 Relative SPRY4‑IT1 expression and its clinical significance in gastric cancer tissues. a SPRY4‑IT1 expression in matched cancerous tissues and 
adjacent noncancerous tissues from 61 gastric cancer patients were measured by qRT‑PCR. Relative gene expression determinations were made 
with the comparative delta CT normalized to GAPDH expression (P = 0.001). b According to the median ratio of relative SPRY4‑IT1 expression 
(0.535) in tumor tissues, SPRY4‑IT1 expression was classified into two groups: relative high‑SPRY4‑IT1 group (n = 30, red column) and relative low‑ 
SPRY4‑IT1 group (n = 31, blue column). Data was presented as fold‑change in tumor tissues relative to normal tissues (P = 0.001). c, d Kaplan–Meier 
overall survival and disease‑free survival curves according to SPRY4‑IT1 expression level. Patients with decreased SPRY4‑IT1 expression (n = 31) 
showed reduced survival times compared with patients with high level of SPRY4‑IT1 expression (n = 31) (P = 0.001 or 0.002, log‑rank test).
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immunoprecipitation (ChIP) assays were performed 
on BGC823 or SGC7901 cells using antibodies against 
DNMT1. As shown in Fig. 2d, enriched DNMT1 immu-
noprecipitation was observed at the promoter of SPRY4-
IT1 in BGC823 and SGC7901 cell lines relative to the 
IgG immunoprecipitates. Acetylated histone H3 (AcH3) 
served as a positive control for ChIP assay. Our findings 
emphasize that DNMT1 mediated DNA methylation 
may be an factor in controlling SPRY4-IT1 expression.
Effect of SPRY4‑IT1 on gastric cancer cells proliferation 
in vitro
In order to manipulate SPRY4-IT1 levels in gastric can-
cer cells, pCDNA-SPRY4-IT1 vector was transfected 
into SGC7901 and BGC823 cells. QRT-PCR analysis 
was performed 48 h post-transfection, and revealed that 
SPRY4-IT1 expression was increased in SGC7901 and 
BGC823 cells. Furthermore, SPRY4-IT1 siRNAs were 
transfected into BGC823 cells to down-regulate endog-
enous SPRY4-IT1 expression, qRT-PCR analysis showed 
that SPRY4-IT1 expression was effectively knocked down 
compared with si-NC control cells (Additional file  2: 
Figure S1A).
To assess the biological role of SPRY4-IT1 in gastric 
cancer, we firstly investigated the effect of over-expres-
sion of SPRY4-IT1 on cell proliferation. MTT assays 
showed that cell growth was significantly impaired 
in pCDNA-SPRY4-IT1 transfected SGC7901 cells or 
BGC823 cells (Fig.  3a), while knockdown of SPRY4-IT1 
expression promoted BGC823 cells proliferation (Addi-
tional file  2: Figure  S1B). Similarly, the results of col-
ony-formation assays showed that clonogenic survival 
was decreased following SPRY4-IT1 over-expression in 
SGC7901 cells or BGC823 cells (Fig. 3b).
SPRY4‑IT1 over‑expression inhibits gastric cancer cells 
tumorigenesis in vivo
To explore whether SPRY4-IT1 could affect tumorigen-
esis, BGC-823 cells transfected with pCDNA-SPRY4-
IT1 or empty vector were used in a nude mice xenograft 
Fig. 2 DNMT1 suppresses SPRY4‑IT1 expression in gastric cancer cells. a QRT‑PCR analysis of SPRY4‑IT1 expression levels in gastric cancer cell lines 
(SGC7901, AGS, MKN‑45, MKN‑28, HGC27 and BGC823) compared with normal human gastric epithelial cell line (GES‑1). b qRT‑PCR analyses of 
SPRY4‑IT1 expression level following treatment of BGC823 and SGC7901 cells with 5‑aza‑CdR. c qRT‑PCR analyses of DNMT1 or SPRY4‑IT1 expression 
level following treatment of BGC823 and SGC7901 cells with si‑DNMT1. d ChIP analyses of DNMT1 binding ability to SPRY4‑IT1 promoter region, and 
anti‑AcH3 was used as the positive control binding to GAPDH promoter region. Fold changes using the 2−ΔΔCt method. IgG was used as a negative 
control. *P < 0.05 and **P < 0.01.
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model. Fifteen days after injection, the tumors formed 
in pCDNA-SPRY4-IT1 group were substantially smaller 
than those in the control group (Fig. 3c). Moreover, the 
mean tumor weight at the end of the experiment was 
markedly lower in the pCDNA-SPRY4-IT1 group com-
pared to the empty vector group (Fig.  3d). In addition, 
the SPRY4-IT1 expression levels were up-regulated in 
tumor tissues collected from pCDNA-SPRY4-IT1 group 
when compared with control group (Additional file  2: 
Figure S1C). Next, immunostaining analysis of the Ki67 
was performed in resected tumor tissues. In comparison 
with that in tumors formed from control cells, pCDNA-
SPRY4-IT1 derived tumors showed significantly reduced 
Ki67 positivity (Fig. 3e).
Effect of SPRY4‑IT1 on gastric cancer cells migration 
and invasion
Cell invasion is a significant aspect of cancer progres-
sion, and involves the migration of tumor cells into con-
tiguous tissues and the dissolution of extracellular matrix 
proteins. To investigate whether SPRY4-IT1 has a direct 
functional role in facilitating gastric cancer cell migra-
tion and invasion, we evaluated cancer cell migration and 
invasion through transwell assays. Increased SPRY4-IT1 
expression levels impeded the migration of SGC7901 and 
BGC823 cells compared with controls. Similarly, invasion 
of SGC7901 and BGC823 cells was also reduced fol-
lowing up-regulation of SPRY4-IT1 expression (Fig.  4a, 
b). Conversely, knockdown of SPRY4-IT1 expression 
enhanced gastric cancer cells migration and invasion 
ability (Additional file 2: Figure 1D).
Increased SPRY4‑IT1 suppresses gastric cancer cell 
metastasis in vivo
To validate the effects of SPRY4-IT1 on the metastasis 
of gastric cancer cells in vivo, BGC823 cells stably trans-
fected with pCDNA-SPRY4-IT1 were injected into nude 
mice via the tail vein. Metastatic nodules on the surface 
of the lungs were counted after 7  weeks. Ectopic over-
expression SPRY4-IT1 resulted in a reduction of the 
number of metastatic nodules compared with those in 
the control group (Fig. 4c, d). This difference was further 
confirmed following examination of the entire lungs, and 
through hematoxylin and eosin (HE) staining of lung sec-
tions (Fig. 4e). Our in vivo data complemented the results 
of functional in vitro studies involving SPRY4-IT1.
SPRY4‑IT1 influences gastric cancer cell epithelial–
mesenchymal transition
As EMT process playing a key role in cancer cells inva-
sion and metastasis, and our previous study indicated 
that lncRNAs also involved in cancer cells invasion via 
Fig. 3 The effect of SPRY4‑IT1 on gastric cancer cells proliferation in vitro and vivo. a MTT assay was performed to determine the proliferation of 
pCDNA‑SPRY4‑IT1 or si‑SPRY4‑IT1 transfected BGC823 and SGC7901 cells. Data represent the mean ± SD from three independent experiments. b 
Colony‑forming growth assay was performed to determine the colony formation ability of pCDNA‑SPRY4‑IT1 transfected BGC823 and SGC7901 
cells. The colonies were counted and captured. c The tumor volume was calculated every 3 days after injection of BGC823 cells stably transfected 
with pCDNA‑SPRY4‑IT1 or empty vector. d Tumor weights are represented as means of tumor weights ± SD. e Tumors developed from pCDNA‑
SPRY4‑IT1 transfected BGC823 cells showed lower ki67 protein levels than tumors developed by control cells. Upper H & E staining; lower: immu‑
nostaining. *P < 0.05 and **P < 0.01.
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regulating EMT [23]. In the present study, we determine 
the expression of the EMT-induced markers in SPRY4-
IT1 over-expressed or down-regulated gastric cancer 
cells. The qRT-PCR results showed that over-expression 
of SPRY4-IT1 could increase E-cadherin and decrease 
Vimentin expression, while knockdown of SPRY4-IT1 
Fig. 4 The effect of SPRY4‑IT1 on gastric cancer cells invasion and metastasis. a, b Transwell assays were used to investigate the changes in 
migratory and invasive abilities of BGC823 and SGC7901 cells transfected with pCDNA‑SPRY4‑IT1 or empty vector. c, d Analysis of an experimental 
metastasis was performed by injecting SPRY4‑IT1‑overexpressing BGC823 cells into nude mice. e Visualization of the entire lungs and HE‑stained 
lung sections. *P < 0.05 and **P < 0.01.
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expression down-regulated E-cadherin expression and 
up-regulated Vimentin expression (Fig.  5a). In addition, 
western blot and Fluorescence immunohistochemistry 
assays showed the same results (Fig. 5b, c and d). These 
data suggested that SPRY4-IT1 contributes to gastric 
cancer cells metastasis may partly via affecting EMT pro-
cess, and further experiments are needed to elucidate the 
potential mechanism.
Discussion
Over the past decade, miRNAs have moved to the fore-
front of ncRNA research in gastric cancer. However, 
lncRNAs in gastric cancer are still an emerging field. 
GAPLINC (gastric adenocarcinoma predictive long 
intergenic noncoding RNA), a 924-bp lncRNA, is highly 
expressed and displays considerable predictive effect in 
the diagnosis and prognosis of gastric cancer. Manipu-
lating GAPLINC expression altered CD44 mRNA abun-
dance and regulated cell migration and proliferation by 
suppressing CD44 expression as a molecular decoy for 
miR211-3p [24]. Similarly, HOTAIR may function as an 
completing endogenous RNA to regulate the expression 
of human epithelial growth factor receptor 2 (HER2) 
through sponging miR-331-3p [25]. FENDRR is down-
regulated in gastric cancer, and decreased expression 
of FENDRR induces FN1 expression, which resulted in 
activation of MMP2/MMP9 [26]. Thus, identification of 
dysregulated lncRNAs will enhance our knowledge of 
lncRNAs function in the progression and metastasis of 
gastric cancer and could be used as new diagnostic or 
therapeutic targets.
SPRY4-IT1 expression was significantly decreased 
in gastric cancer tissues and cell lines. In addition, the 
decreased expression of SPRY4-IT1 was associated 
with poor prognosis and shorter survival time. We also 
showed that DNMT1 could directly bind to SPRY4-IT1 
promoter region and may contribute to the lost expres-
sion of SPRY4-IT1 in gastric cancer cells. Moreover, 
ectopic expression of SPRY4-IT1 led to the significant 
inhibited malignant phenotype of gastric cancer cells 
both in  vitro and vivo. However, SPRY4-IT1 has been 
found to be up-regulated in esophageal squamous cell 
carcinoma, breast cancer and bladder cancer, which sug-
gests that SPRY4-IT1 has an tissue-specific expression 
pattern and may function as oncogene or tumor suppres-
sor in different cancer [20, 27, 28]. Taken together, these 
Fig. 5 SPRY4‑IT1 influences gastric cancer cells epithelial–mesenchymal transition. a qRT‑PCR assays were performed to detect E‑cadherin and 
Vimentin expression in BGC823 cells transfected with pCDNA‑SPRY4‑IT1 or si‑SPRY4‑IT1. b Western blot analysis of E‑cadherin and Vimentin protein 
levels in BGC823 cells transfected with pCDNA‑SPRY4‑IT1 or si‑SPRY4‑IT1. GAPDH protein was used as an internal control. c, d Fluorescence immu‑
nohistochemistry analysis of E‑cadherin and Vimentin protein levels in BGC823 cells transfected with pCDNA‑SPRY4‑IT1 or si‑SPRY4‑IT1. *P < 0.05.
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findings indicate that SPRY4-IT1 could function as a 
tumor suppressor and may be useful as a novel prognos-
tic or progression marker for gastric cancer.
The invasion and metastasis of cancer cells are land-
mark events that involve many changes in cellular behav-
ior, and lead to different steps of the metastatic cascade. 
Although SPRY4-IT1 can suppress migratory and inva-
sive phenotype of gastric cancer cells, the underlying 
mechanism is still elusive. We previously showed that 
SPRY4-IT1 is decreased in NSCLC, and elevation of its 
expression impairs cell invasion and metastasis through 
the regulation of EMT process. EMT is a key step toward 
cancer metastasis, a biological process where epithe-
lial cells lose their polarity and undergo transition into a 
mesenchymal phenotype. Loss of E-cadherin expression 
is a hallmark of EMT process and is likely required for 
enhanced tumor cell motility [29–31]. Perl et al. reported 
that loss of E-cadherin expression coincides with the 
transition from well differentiated adenoma to invasive 
carcinoma in a transgenic mouse model of pancreatic 
beta-cell carcinogenesis [32]. In this study, we deter-
mined the protein levels of these EMT-induced markers 
following SPRY4-IT1 over-expression or knockdown. 
Our results indicate that inhibitory effects of SPRY4-IT1 
on cell migration and invasion were partly associated 
with EMT process.
Conclusions
In summary, we demonstrated that the decreased 
SPRY4-IT1 expression is a common event underly-
ing the progression and metastasis of gastric cancer, 
indicating that SPRY4-IT1 may be an indicator of poor 
survival rate and a negative prognostic factor for gas-
tric cancer patients. SPRY4-IT1 contributed to gas-
tric cancer cells invasion and metastasis may partly 
via regulating epithelial–mesenchymal transition pro-
cess. However, the underlying molecular mechanisms 
through which SPRY4-IT1 involved in EMT requires 
further investigation.
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